CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
121.04
4.61%
Market Trading Hours* (UTC) Opens on Tuesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.30
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Illumina Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 126.89
Open* 126.08
1-Year Change* -44.69%
Day's Range* 121.04 - 126.08
52 wk Range 89.00-238.55
Average Volume (10 days) 2.13M
Average Volume (3 months) 55.45M
Market Cap 21.32B
P/E Ratio -100.00K
Shares Outstanding 158.80M
Revenue 4.47B
EPS -7.12
Dividend (Yield %) N/A
Beta 1.22
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 121.04 -7.11 -5.55% 128.15 128.15 120.47
Apr 12, 2024 126.89 -1.51 -1.18% 128.40 134.67 126.16
Apr 11, 2024 130.57 -1.08 -0.82% 131.65 132.04 127.95
Apr 10, 2024 131.05 3.36 2.63% 127.69 131.27 127.69
Apr 9, 2024 133.47 3.04 2.33% 130.43 134.93 129.57
Apr 8, 2024 130.04 2.79 2.19% 127.25 130.41 126.18
Apr 5, 2024 127.62 3.13 2.51% 124.49 129.46 122.73
Apr 4, 2024 125.82 -3.50 -2.71% 129.32 131.22 125.53
Apr 3, 2024 127.57 0.62 0.49% 126.95 129.94 126.76
Apr 2, 2024 128.39 -2.15 -1.65% 130.54 130.95 127.96
Apr 1, 2024 132.55 -4.49 -3.28% 137.04 137.90 131.27
Mar 28, 2024 137.18 -0.29 -0.21% 137.47 139.95 135.73
Mar 27, 2024 138.47 3.96 2.94% 134.51 138.55 133.83
Mar 26, 2024 133.64 -0.91 -0.68% 134.55 135.54 133.19
Mar 25, 2024 134.00 -2.94 -2.15% 136.94 137.07 132.56
Mar 22, 2024 137.13 1.50 1.11% 135.63 137.42 133.54
Mar 21, 2024 137.34 -2.40 -1.72% 139.74 143.83 136.20
Mar 20, 2024 133.00 0.70 0.53% 132.30 133.17 129.14
Mar 19, 2024 133.02 4.33 3.36% 128.69 135.55 127.65
Mar 18, 2024 130.02 1.80 1.40% 128.22 131.29 125.71

Illumina Inc Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Illumina Inc Earnings Release
Q1 2024 Illumina Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

21:00

Country

US

Event

Q1 2024 Illumina Inc Earnings Call
Q1 2024 Illumina Inc Earnings Call

Forecast

-

Previous

-
Thursday, May 16, 2024

Time (UTC)

17:00

Country

US

Event

Illumina Inc Annual Shareholders Meeting
Illumina Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, May 24, 2024

Time (UTC)

17:00

Country

US

Event

Illumina Inc Annual Shareholders Meeting
Illumina Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 7, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Illumina Inc Earnings Release
Q2 2024 Illumina Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 4584 4526 3239 3543 3333
Revenue 4584 4526 3239 3543 3333
Cost of Revenue, Total 1612 1372 1036 1076 1033
Gross Profit 2972 3154 2203 2467 2300
Total Operating Expense 8763 4649 2659 2504 2450
Selling/General/Admin. Expenses, Total 1297 2092 941 835 794
Research & Development 1321 1185 682 647 623
Unusual Expense (Income) 4533 -54 0
Operating Income -4179 -123 580 1039 883
Interest Income (Expense), Net Non-Operating -121 919 237 75 8
Other, Net -36 88 39 4 3
Net Income Before Taxes -4336 884 856 1118 894
Net Income After Taxes -4404 762 656 990 793
Minority Interest 0 12 44
Net Income Before Extra. Items -4404 762 656 1002 837
Net Income -4404 762 656 1002 826
Income Available to Common Excl. Extra. Items -4404 762 656 1002 837
Income Available to Common Incl. Extra. Items -4404 762 656 1002 826
Diluted Net Income -4404 762 656 1002 826
Diluted Weighted Average Shares 157 151 148 149 149
Diluted EPS Excluding Extraordinary Items -28.051 5.04636 4.43243 6.72483 5.61745
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -9.28376 5.04636 4.43243 6.40391 5.61745
Total Extraordinary Items -11
Jul 2023 Apr 2023 Jan 2023 Oct 2022 Jul 2022
Total revenue 1176 1087 1083 1115 1162
Revenue 1176 1087 1083 1115 1162
Cost of Revenue, Total 444 432 411 398 395
Gross Profit 732 655 672 717 767
Total Operating Expense 1264 1151 1210 4772 1741
Selling/General/Admin. Expenses, Total 432 377 432 146 410
Research & Development 346 341 346 325 327
Operating Income -88 -64 -127 -3657 -579
Interest Income (Expense), Net Non-Operating -3 -17 -31 -5 -36
Other, Net 2 3 -10 -10 -22
Net Income Before Taxes -89 -78 -168 -3672 -637
Net Income After Taxes -234 3 -139 -3816 -535
Net Income Before Extra. Items -234 3 -139 -3816 -535
Net Income -234 3 -139 -3816 -535
Income Available to Common Excl. Extra. Items -234 3 -139 -3816 -535
Income Available to Common Incl. Extra. Items -234 3 -139 -3816 -535
Diluted Net Income -234 3 -139 -3816 -535
Diluted Weighted Average Shares 158 158 157 157 157
Diluted EPS Excluding Extraordinary Items -1.48101 0.01899 -0.88535 -24.3057 -3.40764
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.29589 0.0231 -0.79841 -8.14682 -0.88631
Unusual Expense (Income) 42 1 21 3903 609
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 3561 2713 4483 4451 4490
Cash and Short Term Investments 2037 1339 3472 3414 3512
Cash & Equivalents 2011 1232 1810 2042 1144
Short Term Investments 26 107 1662 1372 2368
Total Receivables, Net 688 648 487 573 514
Accounts Receivable - Trade, Net 688 648 487 573 514
Total Inventory 568 431 372 359 386
Prepaid Expenses 268 295 152 105 78
Total Assets 12252 15217 7585 7316 6959
Property/Plant/Equipment, Total - Net 1744 1696 1454 1444 1075
Property/Plant/Equipment, Total - Gross 2706 2492 2132 2012 1596
Accumulated Depreciation, Total -962 -796 -678 -568 -521
Goodwill, Net 3239 7113 897 824 831
Intangibles, Net 3285 3250 142 145 185
Other Long Term Assets, Total 212 445 609 452 378
Total Current Liabilities 2773 1093 1244 665 1804
Accounts Payable 293 332 192 149 184
Accrued Expenses 890 429 287 263 256
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1248 0 511 0 1107
Other Current Liabilities, Total 342 332 254 253 257
Total Liabilities 5653 4477 2891 2703 3201
Total Long Term Debt 1487 1695 673 1141 890
Long Term Debt 1487 1695 673 1141 890
Minority Interest 0 148
Other Liabilities, Total 1393 1689 974 897 359
Total Equity 6599 10740 4694 4613 3758
Common Stock 2 2 2 2 2
Additional Paid-In Capital 9207 8938 3815 3560 3290
Retained Earnings (Accumulated Deficit) 1142 5485 4723 4067 3083
Treasury Stock - Common -3755 -3702 -3848 -3021 -2616
Unrealized Gain (Loss) 1 4 -2
Other Equity, Total 3 17 1 1 1
Total Liabilities & Shareholders’ Equity 12252 15217 7585 7316 6959
Total Common Shares Outstanding 158 157 146 147 147
Preferred Stock - Non Redeemable, Net 0 0 0 0
Long Term Investments 211
Oct 2023 Jul 2023 Apr 2023 Jan 2023 Oct 2022
Total Current Assets 2506 3223 3172 3561 2487
Cash and Short Term Investments 933 1559 1518 2037 1041
Cash & Equivalents 927 1553 1494 2011 1000
Short Term Investments 6 6 24 26 41
Total Receivables, Net 709 758 682 688 645
Accounts Receivable - Trade, Net 709 758 682 688 645
Total Inventory 615 617 586 568 559
Prepaid Expenses 249 289 386 268 242
Total Assets 10122 11774 11811 12252 11256
Property/Plant/Equipment, Total - Net 1621 1707 1740 1744 1748
Goodwill, Net 2527 3239 3239 3239 3238
Intangibles, Net 3029 3188 3237 3285 3335
Other Long Term Assets, Total 246 212 223 212 222
Total Current Liabilities 1482 2303 2230 2773 2669
Accounts Payable 240 244 242 293 281
Accrued Expenses 935 975 907 890 836
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 750 749 1248 1246
Other Current Liabilities, Total 307 334 332 342 306
Total Liabilities 4224 5219 5118 5653 4525
Total Long Term Debt 1489 1488 1487 1487 495
Long Term Debt 1489 1488 1487 1487 495
Other Liabilities, Total 1253 1428 1401 1393 1361
Total Equity 5898 6555 6693 6599 6731
Common Stock 2 2 2 2 2
Additional Paid-In Capital 9487 9397 9311 9207 9129
Retained Earnings (Accumulated Deficit) 157 911 1145 1142 1281
Treasury Stock - Common -3769 -3767 -3764 -3755 -3720
Other Equity, Total 21 12 -1 3 39
Total Liabilities & Shareholders’ Equity 10122 11774 11811 12252 11256
Total Common Shares Outstanding 158 158 158 158 157
Preferred Stock - Non Redeemable, Net 0
Long Term Investments 193 205 200 211 226
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -4404 762 656 990 782
Cash From Operating Activities 392 545 1080 1051 1142
Cash From Operating Activities 215 176 156 151 140
Amortization 179 75 31 37 39
Deferred Taxes -23 -76 117 11 -18
Non-Cash Items 4221 -240 47 56 217
Cash Taxes Paid 122 233 119 164 99
Changes in Working Capital 204 -152 73 -194 -18
Cash From Investing Activities -591 -1069 -554 745 -1813
Capital Expenditures -466 -208 -189 -209 -296
Other Investing Cash Flow Items, Total -125 -861 -365 954 -1517
Cash From Financing Activities 1000 -51 -766 -897 594
Financing Cash Flow Items -54 -582 -91 -82 18
Issuance (Retirement) of Stock, Net 63 60 -675 -265 -155
Issuance (Retirement) of Debt, Net 991 471 0 -550 731
Foreign Exchange Effects -22 -3 8 -1 -4
Net Change in Cash 779 -578 -232 898 -81
Apr 2023 Jan 2023 Oct 2022 Jul 2022 Apr 2022
Net income/Starting Line 3 -4404 -4265 -449 86
Cash From Operating Activities 10 392 245 297 172
Cash From Operating Activities 57 215 158 102 50
Amortization 50 179 130 83 41
Deferred Taxes -17 -23 -40 -34 -21
Non-Cash Items 112 4221 4044 255 81
Changes in Working Capital -195 204 218 340 -65
Cash From Investing Activities -56 -591 -489 -239 -74
Capital Expenditures -53 -466 -378 -132 -61
Other Investing Cash Flow Items, Total -3 -125 -111 -107 -13
Cash From Financing Activities -473 1000 44 16 21
Financing Cash Flow Items -10 -54 -19 -17 -12
Issuance (Retirement) of Stock, Net 37 63 63 33 33
Issuance (Retirement) of Debt, Net -500 991 0 0 0
Foreign Exchange Effects 2 -22 -32 -17 0
Net Change in Cash -517 779 -232 57 119

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Illumina Company profile

What is Illumina?

Illumina Inc (ILMN) is a San Diego-based U.S. company engaged in the development and marketing of genetic analysis solutions and life science services. Over the past decade it has become a global leader in genomics. Illumina offers a broad portfolio of instruments including NovaSeq Sequencing Systems,HiSeq Sequencing Systems, HiScan Array Scanner and others.

Illumina explains that its aim is “to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago”. The company says it delivers innovative, flexible, and scalable solutions to meet the needs of its customers.These customers include leading genome research centres and a variety of other academic, governmental, pharmaceutical and biotechnology institutions around the world.

In 2017 Forbes ranked Illumina no.18 in its annual list of the world’s most innovative companies. The company was also ranked no.34 in its league table of America's best midsize employers, and no.175 in Forbes’ list of growth champions. As of 6 April 2018, Illumina Inc had a market capitalisation of some $34.14 billion.

Who are the key people at Illumina?

Francis de Souza, who has been President & CEO of Illumina Inc since 2016, is responsible for directing all aspects of company strategy, planning and operations. Other key figures at the company include: Garret Hampton (Executive Vice President, Clinical Genomics); Omead Ostadan (Executive Vice President, Products & Operations); and Marc Stapley (Executive Vice President, Strategy & Corporate Development).

What is the modern history of Illumina?

The company was foundedin 1998 by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee. It acquired Spyder Instruments the following year, and completed its initial public offering in 2000. The acquisition of Solexa Inc followed in 2007, and Epicentre Biotechnologies was acquired in 2011. Roche made an unsolicited bid to buy Illumina for around $5.7 billion in 2012, but both this and a subsequent higher offer were rejected. In 2015, Illumina spun off the blood testing company Grail.

What are the latest developments at Illumina?

In its financial results for fiscal year 2017, Illumnia Inc reported revenue of $2.75 billion, a 15% increase from $2.40 billion in fiscal year 2016.GAAP net income attributable to Illumina stockholders was $726 million, or $4.92 per diluted share, against $463 million or $3.07 per diluted share in 2016.For fiscal year 2018, the company forecast 13-14% revenue growth, and GAAP earnings per diluted share attributable to Illumina stockholders of $4.14-$4.24.

Long-term investors in Illumina saw the value of their holdings increase significantly between 2013 and 2018. From $54 in January 2013, the Illumina share price climbed to $100 in December 2013, $150 in February 2014, and $200 in May 2015. The shares slipped in the second half of 2015, but by March 2018 the stock had recovered to a new high of $253. To find out how the shares are doing right now, follow Capital.com. Our ILMN chart puts all the information at your fingertips.

Where does Illumina operate?

Headquartered in San Diego, California,Illumina's regional subdivisions operate in the United States, Brazil, the United Kingdom, the Netherlands, Singapore, China, Japan and Australia.The company employs over 5,500 people.

Where is Illumina traded?

The company shares are traded on the NASDAQ stock exchange and are constituents of the S&P 500 index. Check out Capital.com for the latest ILMN chart. We’ll keep you up to date and in the picture.

Industry: Advanced Medical Equipment & Technology (NEC)

5200 Illumina Way
SAN DIEGO
CALIFORNIA 92122
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.49 Price
-1.370% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,385.85 Price
+0.150% 1D Chg, %
Long position overnight fee -0.0187%
Short position overnight fee 0.0105%
Overnight fee time 21:00 (UTC)
Spread 0.50

BTC/USD

62,511.50 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,037.99 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading